OS Therapies Inc
OSTX NYSE· Pharmaceutical Preparations
Last close · Oct 27, 2026
$1.23
KIRA · Stoqly’s AI analyst, in plain words
- OS Therapies Inc lost $28.8M in fiscal 2025.
- Free cash flow was −$14.7M in fiscal 2025, — of revenue.
Market cap
$54.0M
P/E
—
Revenue
—
Net income
−$28.8M
Free cash flow
−$14.7M
Operating margin
—
OS Therapies Inc in 30 seconds · fiscal 2025
Does it make a profit?
−$28.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What OS Therapies Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- OS Therapies Inc
- CIK
- 0001795091
OS Therapies Inc · OSTX
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$7.8M | −$8.9M | −$28.8M |
| Diluted EPS | −$1.46 | −$1.28 | −$0.98 |
| Cash | |||
| Cash from operations | −$3.0M | −$7.3M | −$14.2M |
| Capital expenditure | — | — | $0.5M |
| Free cash flow | — | — | −$14.7M |
| Share count change | — | — | 320.9% |
| Debt and strength | |||
| Cash and short-term investments | $0.0M | $5.5M | $0.3M |
| Deposits | — | $0.2M | — |
| Shareholders' equity | −$24.0M | −$3.3M | −$6.1M |
| Current ratio | 0.0x | 1.2x | 0.0x |
| Interest coverage | −1.3x | −3.3x | — |
| Returns and quality | |||
| Altman Z'' | −354.8 | −30.5 | −71.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
OS Therapies Inc · OSTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.23 a share, the company is worth $54.0M.
Source: SEC EDGAR XBRL filings (CIK 0001795091). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.